# EDGAR Filing Document

**Accession Number:** 0001888886
**File Stem:** 0001104659-25-107740
**Filing Date:** 2025-11
**Character Count:** 19772
**Document Hash:** d9485b60a0ec827a2f2ae697c7edf946
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107740.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001104659-25-107740

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251106

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41608
- **FILM NUMBER:** 251458493

**BUSINESS ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 457-1978

**MAIL ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 6, 2025**

**Structure Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-41608** | **98-1480821** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **601 Gateway Blvd.** **, Suite 900**<br> **South San Francisco** **, California** | **94080** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(Registrant's telephone number, including area code): (650) 457-1978**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Name Of Each Exchange<br> **Trading Symbol(s)** | **On Which Registered** |
| American Depositary Shares (ADSs), each representing three<br> ordinary shares, par value $0.0001 per ordinary share | GPCR | Nasdaq Global Market |
| Ordinary shares, par value $0.0001 per share\* |  | Nasdaq Global Market\* |

---

\* Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 2.02 Results of Operations and Financial Condition.**

On November 6, 2025, Structure Therapeutics Inc. (the "Company") issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit <br> No.** | **Description** |
| [99.1](tm2530323d1_ex99-1.htm) | [Press Release dated November 6, 2025](tm2530323d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Structure Therapeutics Inc.** | **Structure Therapeutics Inc.** |
| Date: November 6, 2025 | By: | /s/ Raymond Stevens |
|  |  | Raymond Stevens, Ph.D. |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2530323d1_ex99-1img001.jpg)

**Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights**

*Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025*

*Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025; second oral amylin receptor agonist (ACCG-3535) development candidate declared*

*Strong financial position with cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025*

**SAN FRANCISCO, November 6, 2025–** Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

"We are on schedule to report topline data by year-end 2025 from both the ACCESS and ACCESS II studies of aleniglipron, our once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity," said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. "In parallel, we plan to initiate a Phase 1 study of ACCG-2671, which we believe to be the most advanced oral small molecule amylin receptor agonist in development, and we have declared a second amylin development candidate to further enhance our leadership position with oral small molecules engaging this attractive target. We believe the future of obesity treatment lies in multiple options and includes oral, combinable, and broadly accessible therapies—principles that define and differentiate our pipeline and development strategy. These upcoming milestones mark meaningful progress toward realizing that vision."

**Recent and Upcoming Milestones**

**Aleniglipron (GSBR-1290) - Oral Small Molecule Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight**

*ACCESS and ACCESS II Studies on track for topline 36-week data readouts by year-end 2025*

&nbsp;&nbsp;&nbsp;&nbsp;· **ACCESS** is a Phase 2b randomized placebo-controlled, 36-week study
that enrolled approximately 220 adults with obesity, or overweight with at least one weight-related comorbidity, evaluating doses up to
120 mg of aleniglipron with a four-week titration schedule. An Open Label Extension of the ACCESS study is ongoing.

&nbsp;&nbsp;&nbsp;&nbsp;· **ACCESS II** is a Phase 2 randomized placebo-controlled study that enrolled
approximately 80 adults with obesity, or overweight with at least one weight-related comorbidity, evaluating higher doses of aleniglipron
(180 mg and 240 mg) with a four-week titration schedule. Following the initial 36-week evaluation, patients continue in the study to 44
weeks, which allows for collection of an additional eight weeks of double-blinded safety, tolerability, and efficacy data.

*Three supplementary studies ongoing to generate additional data to competitively position aleniglipron and further support the design of the Phase 3 program*

&nbsp;&nbsp;&nbsp;&nbsp;· **Study to assess a maintenance switching strategy from an approved injectable GLP-1 receptor agonist to aleniglipron** – Enrollment is ongoing in this maintenance switching study which is evaluating the transition
from an approved injectable GLP-1 receptor agonist to once-daily oral aleniglipron for weight loss maintenance. This study will assess
the starting dose and the weight loss maintenance over 12 weeks.

&nbsp;&nbsp;&nbsp;&nbsp;· **Body composition study** – This fully-enrolled Phase 2 randomized
placebo-controlled study is assessing the effect of aleniglipron on body fat loss measured via DEXA over a 40-week evaluation period.
These data will be used to support the inclusion of body composition endpoints into the Phase 3 program.

&nbsp;&nbsp;&nbsp;&nbsp;· **Study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight** – Enrollment is ongoing in this Phase 2 randomized placebo-controlled study which is assessing aleniglipron at doses of up to
240 mg in patients living with obesity or overweight with T2DM. Data from the 38-week study will be used to support the inclusion of a
cohort of patients with T2DM in the Phase 3 obesity program.

**Oral Small Molecule Amylin Receptor Agonists for the Treatment of Obesity or Overweight with Comorbidities**

&nbsp;&nbsp;&nbsp;&nbsp;· **ACCG-2671 –** Investigational new drug enabling activities for
ACCG-2671 are ongoing, with the initiation of a first-in-human Phase 1 clinical study expected by year-end 2025.

&nbsp;&nbsp;&nbsp;&nbsp;· **ACCG-3535 –** A second dual amylin and calcitonin receptor agonist
development candidate, ACCG-3535, has been selected. ACCG-3535 is a unique chemical structure from ACCG-2671. Preclinical ACCG-3535 data
were recently presented at Obesity Week 2025 demonstrating high binding affinity to human amylin and calcitonin receptors and balanced
potency in human amylin and calcitonin receptor functional assays. In addition, ACCG-3535 demonstrated robust food intake suppression
and significant, dose-dependent body weight reduction as a monotherapy in diet-induced obese rats. Combination therapy with semaglutide
(both concurrently and as a subsequent add-on to semaglutide) resulted in superior weight loss compared to semaglutide or ACCG-3535 monotherapy.

**Third Quarter 2025 Financial Highlights**

Cash Position: Cash, cash equivalents and short-term investments totaled $799.0 million as of September 30, 2025. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through at least 2027. For aleniglipron, this includes costs related to the ongoing ACCESS and ACCESS II studies, extension studies, the supplementary studies, and Phase 3 readiness activities, but excludes Phase 3 registrational studies.

Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2025 were $59.0 million, as compared to $32.6 million for the same period in 2024. The increase in R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee expenses (primarily due to an increase in personnel) to support the advancement of our GLP-1R franchise including aleniglipron.

General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2025 were $14.8 million, as compared to $13.2 million for the same period in 2024. The increase in G&A expenses was primarily due to increases in employee expenses as we expanded our infrastructure to drive and support the growth in our operations as a publicly-traded company.

Net Loss: Net loss for the third quarter of 2025 totaled $65.7 million, with non-cash share-based compensation expense of $7.5 million, compared to $34.0 million for the third quarter of 2024 with non-cash share-based compensation expense of $6.0 million.

**About Structure Therapeutics** 

Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit <u>www.structuretx.com</u>.

**Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company's future plans and prospects; the expected timing of topline data readouts from the ACCESS and ACCESS II studies; the planned initiation of the ACCG-2671 Phase 1 study and the timing thereof; the Company's anticipated cash runway and uses of cash; the belief that ACCG-2671 represents one of the most advanced oral small molecule amylin agonists in development; the Company's plans to conduct supplementary aleniglipron studies, including the study design, expected use of data from these studies and timing thereof; the planned initiation of the Phase 2 study in patients with obesity or overweight and T2DM and the timing thereof; and any expectations regarding the safety, efficacy or tolerability of aleniglipron, ACCG-2671, ACCG-3535, and other candidates under development. In addition, when or if used in this press release, the words and phrases "anticipate," "believe," "expect," "may," "on track," "plan," "potential," "prepare," "to be," "will," and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company's planned clinical studies, the Company's ability to advance aleniglipron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company's therapeutic candidates; competitive products or approaches limiting the commercial value of the Company's product candidates; the timing and results of preclinical and clinical studies; the Company's ability to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeconomic conditions, including as a result of tariffs and various global conflicts; the Company's ability to protect its intellectual property; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

**STRUCTURE THERAPEUTICS INC.**

**Condensed Consolidated Statements of Operations**

(unaudited)

(In thousands)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **THREE MONTHS ENDED** | **THREE MONTHS ENDED** | **NINE MONTHS ENDED** | **NINE MONTHS ENDED** |
|  | **SEPTEMBER 30,** | **SEPTEMBER 30,** | **SEPTEMBER 30,** | **SEPTEMBER 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | $58989 | $32598 | $156566 | $75327 |
| &nbsp;&nbsp;&nbsp;General and administrative | 14798 | 13238 | 43983 | 35840 |
| Total operating expenses | 73787 | 45836 | 200549 | 111167 |
| Loss from operations | (73787) | (45836) | (200549) | (111167) |
| Interest and other income, net | 8183 | 11951 | 26688 | 25294 |
| Loss before provision for income taxes | (65604) | (33885) | (173861) | (85873) |
| Provision for income taxes | 108 | 92 | 345 | 174 |
| Net loss | $(65712) | $(33977) | $(174206) | $(86047) |

---

**STRUCTURE THERAPEUTICS INC.**

**Condensed Consolidated Balance Sheet Data**

(unaudited)

(In thousands)

---

| | | |
|:---|:---|:---|
|  | **SEPTEMBER 30,**<br>**2025** | **DECEMBER 31,**<br>**2024** |
| **Assets** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash, cash equivalents and short-term investments | $799043 | $883518 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 14979 | 7693 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 814022 | 891211 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 4675 | 3478 |
| &nbsp;&nbsp;&nbsp;Operating right-of-use assets | 6863 | 3535 |
| &nbsp;&nbsp;&nbsp;Other non-current assets | 6599 | 5106 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $832159 | $903330 |
| **Liabilities and shareholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $17796 | $8024 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 36929 | 26299 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | 2802 | 1698 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 57527 | 36021 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, net of current portion | 4288 | 2164 |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | 325 | 302 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 62140 | 38487 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 770019 | 864843 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and shareholders' equity | $832159 | $903330 |

---

**Investors:**

Danielle Keatley

Structure Therapeutics Inc.

ir@structuretx.com

**Media:**

Dan Budwick

1AB

Dan@1abmedia.com